(GRDN) Guardian Pharmacy Services - Ratings and Ratios

Guardian Pharmacy Services, Inc. is a pioneering pharmacy service company that leverages technology to provide personalized care to residents in long-term health care facilities (LTCFs) across the United States. By focusing on lower acuity LTCFs, such as assisted living facilities, behavioral health facilities, and group homes, the company has established a niche for itself in the healthcare industry. Its suite of services, including Guardian Compass, GuardianShield Programs, Order Entry QA Analyzer, and Medication Spend Analyzer, demonstrates a commitment to optimizing business operations, improving patient care, and reducing medication errors.

The companys technology-enabled services are designed to streamline clinical, drug dispensing, and administration processes, ultimately enhancing the quality of life for LTCF residents. By harnessing data from its data warehouse, Guardian Compass provides actionable insights that enable local pharmacies to plan, track, and optimize their operations. Meanwhile, the Order Entry QA Analyzer utilizes real-time rules-engine technology to detect potential errors and omissions, ensuring a high level of quality control. With a presence in the US market since 2003, Guardian Pharmacy Services, Inc. has established itself as a trusted partner for LTCFs, with its headquarters in Atlanta, Georgia.

Analyzing the available and , we can infer that GRDNs stock has experienced fluctuations in recent times. The current price of $19.69 is below its 20-day and 50-day simple moving averages (SMA), indicating a potential downtrend. However, the stocks relative position to its 52-week high and low ($26.52 and $16.00, respectively) suggests that it is still within a reasonable range. Considering the companys market capitalization of $1.25 billion and its classification within the Drug Retail sub-industry, we can anticipate that GRDNs stock performance will be influenced by the overall healthcare sector trends.

Forecasting GRDNs future performance, we can expect the stock to potentially rebound towards its 20-day SMA of $21.88, given the current ATR of 1.39 (7.08% volatility). However, the absence of a reported P/E ratio and a negative RoE of -74.40 raises concerns about the companys profitability. As a Trading Analyst, it is essential to weigh these factors and consider the potential for GRDN to adapt its business model to address these challenges. A more detailed analysis of the companys financials and industry trends would be necessary to make a more informed prediction about GRDNs future stock performance.